Virginia cop claims AbbVie drug triggered his psychosis; Novartis nabs Bexsero rec in Australia; FDA clears Roche HPV test as Pap replacement;

@FiercePharma: Yesterday's top-read special report: The top 10 pharma companies by 2013 revenue. Read | Follow @FiercePharma

@TracyStaton: Uh-oh for Merck animal health: Hundreds more Zilmax-fed cattle died than Merck reported to FDA. Story via Reuters | Follow @TracyStaton

@EricPFierce: Sun Pharma plant joins FDA village of the banned. Story via FiercePharmaManufacuring | Follow @EricPFierce

@CarlyHFierce: Missed yesterday's issue of FiercePharmaMarketing? Got you covered. | Follow @CarlyHFierce

> A Virginia Beach, VA, police officer sued AbbVie ($ABBV) and its former parent Abbott Laboratories ($ABT), claiming that its antibiotic Biaxin triggered his psychotic episode, during which he stabbed two firefighters. Report

> Novartis ($NVS) won a clinical recommendation in Australia for routine use of its Bexsero vaccine against meningitis B in infants and adolescents. Report

> An FDA panel recommended Roche's ($RHHBY) human papilloma virus diagnostic test as an alternative to the common cervical cancer screening method, the Pap test. Release

> Belgium-based UCB launched its anti-inflammatory drug Cimzia (certolizumab) in the U.K. and Ireland as a treatment for psoriatic arthritis. Report

> Scotland's cost-effectiveness panel decided to recommend Sanofi's ($SNY) colon cancer treatment Zaltrap after all. Report

Medical Device News

@FierceMedDev: Add debt restructuring to Quest Diagnostics' numerous moves to improve things. Story | Follow @FierceMedDev

@MarkHFierce: Philips ventilator recall gets slapped with the FDA's Class I recall status--its most serious designation. More | Follow @MarkHFierce

@MichaelGFierce: NeuroDerm preps for Parkinson's patch PhII trial. Read in FierceDrugDelivery. | Follow @MichaelGFierce

@EmilyWFierce: Roche gets glowing reviews from FDA panel for frontline HPV test. Article | Follow @EmilyWFierce

> Quest Diagnostics is proposing a $600M debt refinancing. More

> Vaginal mesh lawsuits are escalating in Scotland. Piece

Biotech News

@FierceBiotech: Sage snags $38M from A-list VCs to bankroll its seizure drugs. More | Follow @FierceBiotech

@JohnCFierce: Circassia's record-busting $332M IPO inspires hopes of U.K. renaissance. News | Follow @JohnCFierce

@DamianFierce: Vectura bags respiratory biotech Activaero for $181M. Story | Follow @DamianFierce

@EmilyMFierce: Despite progress, tuberculosis persists in West European cities. Piece via Reuters | Follow @EmilyMFierce

> GlaxoSmithKline maps a route to regulators with positive PhIII asthma data. Article

> Tesaro pays $17M to team with AnaptysBio on cancer immunotherapies. More

Pharma Manufacturing News

> CMO born from $2.6 billion merger comes on the scene as DPx. Story

> Sun Pharma plant joins the FDA list of banned Indian facilities. News

> FDA says Indian drugmaker made up data for API tests. Piece

> Bayer expands German plants as it preps for new hemophilia treatments. More

> Hikma hits the jackpot with doxycycline shortage. Coverage

> Pharma cargo theft takes new spike. Brief

Vaccines News

> Daiichi misses H5N1 vaccine production goal after low yields slash output. Story

> Analysts offer mixed reactions to Pfizer's Prevnar 13 data close-up. Article

> Northwest Bio, NewLink proceed with cancer vax trials to mixed reviews. News

> ImmusanT waits on early clinical data for its celiac disease vaccine. Story

> Study: Vaccinating diabetics against flu cuts risk of death by 28%. Article

> U.K. mulls adopting a 2-dose model for HPV vaccination. Brief

And Finally... "Love hormone" oxytocin could help treat anorexia nervosa, researchers said. Report

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.